WEKO3
アイテム
The effectiveness of interferon-alpha subtypes alternation for metastasis from renal cell carcinoma
https://doi.org/10.24517/00053663
https://doi.org/10.24517/00053663856ba941-d312-44cf-8951-fb09b7643ecd
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ME-PR-NAMIKI-M-323.pdf (307.0 kB)
|
.png)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2019-03-08 | |||||||||||||||
| タイトル | ||||||||||||||||
| タイトル | The effectiveness of interferon-alpha subtypes alternation for metastasis from renal cell carcinoma | |||||||||||||||
| 言語 | ||||||||||||||||
| 言語 | eng | |||||||||||||||
| 資源タイプ | ||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||
| 資源タイプ | journal article | |||||||||||||||
| ID登録 | ||||||||||||||||
| ID登録 | 10.24517/00053663 | |||||||||||||||
| ID登録タイプ | JaLC | |||||||||||||||
| 著者 |
Kadono, Yoshifumi
× Kadono, Yoshifumi× Miwa, Sotaro× Shima, Takashi× Konaka, Hiroyuki× Mizokami, Atsushi× Yotsuyanagi, Satoshi× Hirata, Akio× Takase, Yasukazu× Sugata, Toshiaki× Shimamura, Masayoshi× Namiki, Mikio |
|||||||||||||||
| 著者別表示 |
角野, 佳史
× 角野, 佳史
× 三輪, 聰太郎
× 小中, 弘之
× 溝上, 敦
× 並木, 幹夫
|
|||||||||||||||
| 提供者所属 | ||||||||||||||||
| 内容記述タイプ | Other | |||||||||||||||
| 内容記述 | 金沢大学医薬保健研究域医学系 | |||||||||||||||
| 書誌情報 |
Biomedical Research (Japan) 巻 33, 号 6, p. 323-328, 発行日 2012 |
|||||||||||||||
| ISSN | ||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||
| 収録物識別子 | 0388-6107 | |||||||||||||||
| NCID | ||||||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||||||
| 収録物識別子 | AA00110128 | |||||||||||||||
| DOI | ||||||||||||||||
| 関連タイプ | isIdenticalTo | |||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||
| 関連識別子 | 10.2220/biomedres.33.323 | |||||||||||||||
| 出版者 | ||||||||||||||||
| 出版者 | Biomedical Research Foundation | |||||||||||||||
| 抄録 | ||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||
| 内容記述 | Interferon-alpha (IFN-α) has been used in systemic treatment for metastatic renal cell carcinoma (mRCC). IFN-α has at least 14 subtypes, each of which has different biological activity. There have been reports that mRCC resistant to an IFN-α treatment responded to another IFN-α subtype. This study was performed to evaluate the effectiveness of alternation of different IFN-α subtypes for mRCC that did not respond to initial IFN-α treatment. In our department and associated institutions, alternating therapy of IFN-α was provided for 15 initial IFN-α refractory mRCC cases from June 2005 to September 2008. Among the 15 patients, the effects of alternating IFN-α therapy were as follows: complete response (CR), 0 cases; partial response (PR), 1 case; stable disease (SD), 3 cases; progressive disease (PD), 11 cases. The response rate (CR+PR) was 7% and disease control rate (CR+PR+SD) was 27%. No severe side effects were observed in any of these cases. The PR case is still in PR 21 months after alternating IFN-α therapy. Among the three SD cases, one has continued SD for 14 months and the other for 12 months. Alternating IFN-α therapy for mRCC can be attempted even if other cytokines are not effective. © 2012 Biomedical Research Press. | |||||||||||||||
| 権利 | ||||||||||||||||
| 権利情報 | Copyright © 2012 Biomedical Research Press. | |||||||||||||||
| 著者版フラグ | ||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||
| 関連URI | ||||||||||||||||
| 識別子タイプ | URI | |||||||||||||||
| 関連識別子 | https://www.jstage.jst.go.jp/browse/biomedres/-char/ja/ | |||||||||||||||
| 関連名称 | https://www.jstage.jst.go.jp/browse/biomedres/-char/ja/ | |||||||||||||||
